Summary
Signal counts
Assets tracked: 4
Watchlist assets: 3
Registry stop assets: 3
Sponsor overview
Mayo Clinic
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00814892 | https://clinicaltrials.gov/study/NCT03130348 | https://clinicaltrials.gov/study/NCT00792142 | https://clinicaltrials.gov/study/NCT00075881 | https://clinicaltrials.gov/study/NCT03713294 | https://clinicaltrials.gov/study/NCT03232307 | https://clinicaltrials.gov/study/NCT01867606
Assets
Linked programs
- allogeneic tumor cell vaccine: Registry Stop Signal (3/5)
- Bortezomib: Registry Stop Signal (4/5)
- Dexamethasone: Registry Stop Signal (4/5)
- serum-derived bovine immunoglobulin protein isolate: Low Signal (0/5)